Aberrations in sonic hedgehog (shh) signaling are known to be associated with certain types of cancer, including acute myeloid leukemia (AML). In this interview, Jorge Cortes, MD, of the MD Anderson Cancer Center, Houston, TX, discusses his presentation on the therapeutic targeting of this pathway at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL. Prof. Cortes provides a background on the normal functioning of the hedgehog signaling pathway and the alterations seen in AML. He highlights the progress in targeting this pathway in skin cancer, moving on to the situation in AML, for which the Smoothened (SMO) inhibitor glasdegib is being tested.
Targeting sonic hedgehog signaling in AML
